Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-On Our Radar: Drugmakers, Ryanair, Worldline

Mon, 03rd Feb 2020 08:00

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters and anchored today by Joice Alves. Reach her on Messenger to share your
thoughts on market moves: joice.alves.thomsonreuters.com@reuters.net

ON OUR RADAR: UK, DRUGMAKERS, RYANAIR, WORLDLINE (0755 GMT)

Futures point to a higher open in Europe after Brexit and reports on Saturday that Boris
Johnson would consider a looser trade agreement with the European Union, similar to the bloc's
ties with Australia, rather than follow EU rules to reach a closer deal.

Johnson is expected to give a speech on trade today. Traders are also expecting some
eurozone and UK PMI numbers, which will be released this morning.

In terms of single stocks, Siemens Healthineers shares are down 6.5% in early
Frankfurt trade after it said Q1 profit fell on higher diagnostic gear costs

Meantime, UK drugmaker GlaxoSmithKline is also on the radar after it said it is
collaborating with the Coalition for Epidemic Preparedness Innovations to develop a vaccine for
the coronavirus outbreak.

In terms of M&A, traders see payments company Ingenico shares rallying 17% after
Worldline agreed to buy its French peer in a deal which would create a new European
champion in the sector.

Ryanair shares are seen 1-2% higher after 3Q revenues beat estimates but the company
said it may have to push back its long-term target of flying 200 million passengers per year by
as much as two years due to delays in the delivery of Boeing's <BA.N 737> MAX jet.

Some other earning results could move stocks: Swedish telecoms operator Tele2 Q4
earnings beat forecast company launched a new restructuring programme.

Julius Baer is seen 2% lower as it said it will cut 300 jobs after 2019 profit
drop.

Other corporate headlines:

Sri Lanka to probe graft accusations over Airbus deal

Imperial Brands names Stefan Bomhard CEO

(Joice Alves)

*****

EUROPEAN STOCKS SEEN HIGHER (0650 GMT)

European bourses are expected to open higher this morning as investors get some relief from
the fact that the UK left the euro zone ending years of uncertainty around the Brexit outcome.

Fears from Asia will likely put a brake on the enthusiasm. As traders in Asia returned from
a week-long Lunar Year break, shares across the region and global commodity prices stumbled on
concerns that the coronavirus epidemic will hit demand in the world's second-largest economy.

Investors will also have their eyes on PMI data from the euro zone, Germany, France, Italy,
Netherlands and Spain that will be released this morning.

Back in the UK, today's PMI data will likely see little market reaction as services PMI due
Wednesday matters more for the economy.

Financial spreadbetters at IG expect London's FTSE to open 15 points higher at 7,286,
Frankfurt's DAX to open 21 points up at 12,981 and Paris' CAC to open 12 points higher at
5,806.

(Joice Alves)

*****?
(Reporting by Danilo Masoni, Joice Alves, Julien Ponthus and Thyagaraju Adinarayan)

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.